01513.HK
Livzon Pharmaceutical Group, Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 23.18
+4.32%Year over year
Reported trailing growth
- Revenue
- -14.1%
- EBITDA
- -21.0%
- EBIT
- -29.6%
- EPS
- -26.8%
- Free cash flow
- +8.7%
- Operating cash flow
- +25.1%
Forward estimates
Based on analyst estimates
- Revenue
- -53.9%
- EBITDA
- -52.0%
- EPS
- -51.3%
Three-year CAGR
- Revenue
- -1.6%
- EBITDA
- +0.2%
- EBIT
- +7.8%
- Net income
- +1.9%
- EPS
- +3.6%
- Free cash flow
- +11.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026